1 Annual Report 2025 Review of Operations Directors’ Report Chairman’s Letter CEO’s Report Financial Report Shareholder Information Chairman’s Letter We are delighted to present INOVIQ’s Annual Report for the financial year ended 30 June 2025. Mr David Williams Chairman Dear shareholder, INOVIQ achieved significant progress in FY25, with major milestones in both diagnostics and therapeutics. The EXOOC™ ovarian cancer screening test demonstrated 100% sensitivity for early-stage disease with no false positives, positioning it as a potential breakthrough in non-invasive cancer screening. The CAR-exosome therapeutic program showed promising results, killing 88% of triple-negative breast cancer and non-small cell lung cancer cells in vitro. The company also expanded its EXO-NET® research tool business in partnership with Promega Corporation, and neuCA15-3 data was published in a peer-reviewed journal. On the corporate side, INOVIQ appointed key leaders, including Mary Harney as Non-Executive Director and Dr Emma Ball as Chief Commercial Officer, and established a Medical and Scientific Advisory Board to guide future development. Financially, INOVIQ ended FY25 with $6.5 million in cash but reported a net loss of $6.9 million as it continued to invest heavily in its programs. Looking ahead, INOVIQ’s FY26 priorities include expanding the EXO-NET® business, advancing EXO-OC™ toward commercialisation, progressing CAR-exosome therapy, and forming strategic partnerships to accelerate diagnostic tech commercialisation. INOVIQ is well-positioned for future growth, with an experienced leadership team and a promising multi-product pipeline. Thank you to our shareholders for your continued support as we enter this exciting phase of growth and innovation. FY25 ACHIEVEMENTS Expand exosome platform across research tools, diagnostics and therapeutics › EXO-NET customers hit 60 in pre-launch phase › EXO-OC test se 77% / sp >99.6% all-stages and detects 100% Stage I/II › CAR-EVs kill 88% TNBC & NSCLC cells in vitro and collaboration with Peter Mac › NeuCA15-3 peer reviewed publication › Advisory Board established & leadership team expanded FY26 CATALYSTS Partner diagnostic programs, accelerate development of exosome therapeutics and grow revenues › EXO-NET >200% customer growth & first diagnostic partner › Partner EXO-OC test for LDT commercialisation and progress IVD development › in vivo data for CAR-EV in TNBC mouse model & commence INDenabling studies › Partner NeuCA15-3 test 3-YEAR OBJECTIVES INOVIQ established as a leading exosome company with best-in-class diagnostics and therapeutics for cancer › EXO-NET established as a best- in-class EV isolation technology › EXO-OC established as a bestin-class screening test for ovarian cancer › CAR-NK-EV validated as a potential first-in-class exosome therapeutic for cancer › NeuCA15-3 generating partner revenue › Yoy growth across partner, product and revenue metrics
RkJQdWJsaXNoZXIy MjE2NDg3